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Background: Chronic obstructive pulmonary disease (COPD) has become a major public health problem
worldwide because of its high and increasing prevalence, morbidity, and mortality. Little attention has been paid to
earlier stages of COPD or before it has developed. Reportedly, TCM may have some advantages in relieving
symptoms and reducing the incidence of COPD exacerbations. We postulate that patients with COPD will benefit
from therapy with TCM treatment according to syndrome differentiation.
Methods and design: A prospective, multi-center, double-blinded and randomized controlled method will be used
to test the therapeutic effects of TCM treatment according to syndrome differentiation. A total of 504 patients will
be enrolled into this study with 252 in each treatment group. Patients will receive medication according to their
assigned group. TCM for COPD will be administered twice daily over 52 weeks, and all patients will follow the
treatment program for 52 weeks. The FEV1 and exacerbations will be used as the primary outcome measures. The
quality of life and the Modified Medical Research Council (MMRC) Dyspnea Scale, and the 6-min walk test (6MWD)
will be used as the secondary outcome measures.
Discussion: We postulate that patients with COPD will benefit from therapy with TCM treatment according to
syndrome differentiation.
Trial registration: This study is registered at ClinicalTrials.gov, NCT01486186
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Chronic obstructive pulmonary disease (COPD) has be-
come a major public health problem worldwide because
of its high and increasing prevalence, morbidity and
mortality [1,2]. A recent report estimated that the global
prevalence of COPD (stage II or over) is about 10% (12%
in men and 9% in women) [3]. In China, COPD affects
8% of the population aged 40 and above [4], and is one
of the top diseases in the World Health Organization’s
ranking of burden of diseases [5]. It is therefore* Correspondence: li_js8@163.com
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distribution, and reproduction in any mediumnecessary to develop a reliable intervention strategy for
the prevention and management of COPD to reduce the
burden of this disease.
Current interventions for COPD (such as smoking
cessation, rehabilitation, nutrition support, drug treat-
ments and psychosocial aids) are mainly on a case-by-
case basis among patients who have already developed
moderately or severely symptomatic COPD, while little
attention has been paid to earlier stages of the disease or
before it has developed. Although there has been some
progress with case-based or hospital-based interventions
[such as improvements in exercise capacity, forced ex-
piratory volume in 1 s (FEV1) and health-related quality
of life, fewer hospital admissions and acute exacerba-
tions, and lower all-cause mortality] [6-9], such effortstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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eral population in China. Few patients are diagnosed
until they develop severe symptoms and signs, and pul-
monary function tests are not routinely performed.
Traditional Chinese medicine (TCM) is very popularly
used for COPD in Asia, and reportedly TCM may have
some advantages in relieving symptoms, reducing the inci-
dence of COPD exacerbations and improving the quality of
life for COPD patients [10,11].
We report in this article on a multi-center, randomized,
double-blinded, placebo-controlled trial of traditional Chin-
ese medicine treatment with syndrome differentiation to
test the hypothesis that patients with COPD will benefit
from the therapy with TCM.
Objective
To determine whether treatment with TCM with syn-
drome differentiation reduces exacerbation frequency.
Methods and design
Study design
This clinical trial has a multi-centered, randomized, double-
blinded, placebo-controlled design. The study design will
integrate rigorous, contemporary clinical research method-
ology in accord with the principles set out in the Declar-
ation of Helsinki and the Good Clinical Practice guidelines
according to the theory that guides the appropriate use of
TCM in clinical practice. Reporting will be guided by the
CONSORT statement [12,13]. Subjects will be enrolled at
12 hospitals: (1) the First Affiliated Hospital of Henan Uni-
versity of TCM, (2) TCM Hospital of Xinjiang Uygur Au-
tonomous Region; (3) the First Affiliated Hospital of Anhui
University of TCM; (4) Xiyuan Hospital of the China Acad-
emy of Chinese Medical Sciences; (5) Jiangsu Province Hos-
pital of TCM; (6) Shanghai Shuguang Hospital affiliated
with Shanghai University of Traditional Chinese Medicine;
(7) the Second Affiliated Hospital of Guiyang College of
TCM; (8) Jilin Academy of Traditional Chinese Medicine;
(9) Shanxi Sheng Zhongyi Hospital; (10) the First Teaching
Hospital of Tianjing University of TCM; (11) the First
Affiliated Hospital of Guangzhou University of TCM; (12)
Jiangxi Province Hospital of TCM. This study will be con-
ducted at 12 sites in China. Twelve hospitals in China will
randomly assign 504 patients with COPD at a ratio of 1:1
into the TCM treatment or matching placebo group. Con-
senting eligible participants will be enrolled for 2 weeks and
will be required to attend seven visits in total. The trial is
designed in two phases, 52 weeks of treatment with either
TCM for COPD or placebo granules, and 52 weeks of
follow-up.
Study duration
Ongoing recruitment will occur for a maximum
period of 18 months (between July 2011 andDecember 2013) or until a sample of 504 individuals
has been randomized.
Subjects
A total of 504 participants will be recruited through
local advertising and doctor referrals from hospital out-
patients and general practice clinics. Interested partici-
pants can telephone or email the trial coordinators at
the corresponding sites for further information. Partici-
pant information and consent forms will be sent to
interested individuals to read over prior to scheduling
their first visit.
Inclusion criteria for participation in the trial
The inclusion criteria are as follows: (1) a confirmed
diagnosis of mild/moderate COPD; (2) males and females
aged between 40 and 80 years; (3) meeting the TCM diag-
nostic criteria (syndrome differentiation includes lung qi
deficiency, pulmonosplenic qi deficiency and insufficient
lung and kidney qi syndromes); (4) not having participated
in other interventional trials in the previous 1 month; (5)
giving written informed consent to participate.
Exclusion criteria
Exclusion criteria include: (1) pregnant or breast-feeding
women; (2) any psychiatric condition rendering the pa-
tient unable to understand the nature, scope and possible
consequences of the study; (3) complication of severe
heart failure (NYHA heart function class IV) or unstable
hemodynamics; (4) complication of bronchial asthma,
bronchiectasis or active tuberculosis, obliterative bron-
chiolitis or diffuse pantothenic bronchiolitis, pneumo-
thorax, pleural effusion or pulmonary embolism; (5)
complication of neuromuscular disorders affecting respir-
ation or of tumors; (6) complication of serious hepatic and
renal diseases; (7) long periods of bed rest; (8) use of oral
or parenteral corticosteroids in the 1 month before the
first visit; (9) having immunodeficiency; (10) participating
in other trials or being allergic to the used medicine.
This study is to be conducted in accordance with patient
protection as outlined in the Declaration of Helsinki and
approved by the appropriate Institutional Review Boards.
Each participant will sign the written informed consent
form before undergoing any examinations or study proce-
dures, in compliance with Good Clinical Practice. Patients
who initially meet the eligibility criteria are then to
complete the additional baseline testing and will be rando-
mized into either the treatment or control group.
Ethics issues
This study has been approved by the Ethics Committee
of the First Affiliated Hospital of Henan University of
TCM (no: 2011HL-034). Each participating center
obtained local institutional review board approval. All
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Interventions
Eligible patients will be randomized to one of the two arms:
receiving a placebo or a Chinese medical herb. An herbal
extract will be given twice daily for 52 weeks. There are
three recipes for the three traditional Chinese syndromes:
lung qi deficiency, pulmonosplenic qi deficiency, and lung
and kidney qi insufficiency syndromes. The experimental
group will receive three types of TCM: Baofei granules,
Bufeijianpi granules and Bufeiyishen granules. The placebo
comparison group will receive placebo Chinese medicine in
addition to best care according to the clinical guidelines for
COPD patients.
Randomization of subjects will occur centrally using a
random number generator and will be stratified by syn-
drome differentiation of TCM (a syndrome, as related to
illnesses in Western medicine, is composed of a set of
signs and/or symptoms classified by Traditional Chinese
Medicine practitioners. TCM syndrome differentiation is
based on symptoms and helps to identify a disease
subset).
Randomization and allocation
Treatment allocation occurs when the study participant
meets the inclusion criteria and signs the informed con-
sent form. The teletherapist will then register the partici-
pant into the database, which in turn asks if they are
ready to be randomized. After the teletherapist enters
“yes,” the site-specific randomization program behind
the form displays the participant's group assignment
number (placebo versus Chinese medical herb). Site-
specific randomization lists will be computer-generated
(i.e., generated by an individualized basic visual code
program) and concealed from the researchers by a senior
data manager who is not involved in the study. This in-
formation will remain confidential and will not be
shared with the study sites, in concordance with the
CONSORT guidelines. This trial uses a prospective, ran-
domized, double-blinded design. The allocation list will
be protected by password access files and held by an in-
dependent non-investigator. In the event of an emer-
gency medical situation, the individual’s randomization
code and group allocation can be identified.
Sample size
The sample size calculation is based on the annual
decline of mean forced expiratory volume in 1 s
(FEV1) in COPD subjects. The previous study showed
that the mean rate of change in FEV1 was a decline
of 51 ml per year in patients with TCM treatment
and 131 ml per year in patients with usual care with
mild/moderate COPD. According to the sample sizeof the estimation formula n ¼ 2 uaþuφð Þσδ
 2
, n1 = n2 = 2
(1.64 + 1.28)2 × 0.282/0.082 = 209. It is estimated that a
sample size of 209 subjects per group will be
required, considering 20% drop out and exit. This
results in 504 in total. Intention-to-treat analysis will
be applied to minimize bias due to drop-outs.
Outcome measurements
Primary outcome measure
Pulmonary function (FEV1) Pulmonary function
(FEV1) will be evaluated prior to treatment, at weeks 26
and 52 of the treatment phase, and weeks 26 and 52 of
the follow-up phase.
Exacerbation Frequency of exacerbations of COPD will
be evaluated at weeks 26 and 52 of the treatment phase,
and weeks 26 and 52 of the follow-up phase. If the inter-
val between two onsets of acute exacerbation is within
5 days, it can be counted as one period of acute
exacerbation.
Secondary outcome measure
Dyspnea The Dyspnea Scale Questionnaire, which was
first developed by the British Medical Research Council
(MRC) and later revised by the American Thoracic Soci-
ety (MMRC), will be observed and recorded prior to
treatment at weeks 13, 26, 39 and 52 of the treatment
phase, and weeks 26 and 52 of the follow-up phase.
Quality of life (QOL) The secondary outcome measures
will be QOL improvement assessed by using the COPD
Assessment Test (CAT) [14] and short-form 36-item
questionnaire (SF-36) [15]. They will be observed and
recorded prior to treatment, at weeks 13, 26, 39 and 52
of the treatment phase, and weeks 26 and 52 of the
follow-up phase.
The 6-Min walking distance test (6MWD) In patients
with COPD, the 6 MWD is a good predictor of health-
care utilization. The 6MWD will be observed and
recorded to prior treatment, at weeks 13, 26, 39 and 52
of the treatment phase, and weeks 26 and 52 of the
follow-up phase.
Adverse event reporting
pirometry at each site will be conducted using Spir-
oUSB™ (CareFusion) and Spida5W software. Routine cali-
bration and standard operating procedures will be
uniformly undertaken at each site. Participants will be
advised not to use respiratory medications for several
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surements will be taken at each visit, pre-bronchodilator
and post-bronchodilator (post 400 μg of inhaled
salbutamol).
Any adverse events will be listed in the trial record
and followed up to completion by the trial coordinators
and respiratory physicians. Adverse event details will be
scored using a six-point scale: 0 = none, 1 =minimal,
2 =mild, 3 =moderate, 4 = severe and 5 = extremely se-
vere. Participants will be able to report adverse events
anytime throughout the trial and will receive advice ac-
cordingly. Serious adverse events will be reported to the
reviewing Human Research Ethics Committee (HREC)
and site HRECs within the timeframe specified by the
lead HREC.
Throughout the study period, trial coordinators will
contact the participant’s usual treating doctor to record
relevant data on presentations and exacerbations.
To assist with outcome documentation and medica-
tion compliance, participants will be given a participant
diary for the duration of the trial. They will be asked to
record trial medication and relief medication usage as
well as any new medications they commence during the
trial.
Participants may withdraw from the study for any rea-
son at any time without repercussions. They will only be
withdrawn by investigators if it is deemed medically un-
safe for them to continue. Dropouts will not be replaced.
Statistical analysis
Descriptive statistical analysis will be performed for all the
study variables. We will calculate the mean, median and
standard deviations for quantitative variables, and the abso-
lute and relative frequency for qualitative variables.
We use SPSS 19.0 (license no.: 6f1d84c801f1e6010dc,
SPSS Inc., Chicago, IL, USA) to statistically analyze the
data. An intention-to-treat analysis will be applied using
the Last Observation Carried Forward (LOCF) method.
Analysis of covariance with baseline as covariate will be
used to assess differences in treatment outcomes be-
tween the two groups at each of these time points. To
correct for inflated risk of type 1 error, multiple com-
parison procedures suggested by Ludbrook et al. will be
used [16]. The use of relief medication during the trial
will be investigated for its effect on the outcome mea-
sures by using it as a covariate in the statistical analysis.
A Data Safety Monitoring Board has been established to
assess the progress of the trial, particularly safety
endpoints.
Discussion
Chronic obstructive pulmonary disease (COPD) remains
a major public health problem. The aim of COPD treat-
ment should be to decrease symptoms and exacerbations,reduce the risk of hospital admission, increase lung func-
tion and improve QOL. Recently, the approach to therapy
has focused on symptomatic relief.
Traditional Chinese medicine (TCM), as a system of
medicine, has been a form of health care in China and
its neighboring countries for several thousand years.
Some TCM therapy, such as Tanreqing injections, has
been reported to be of some benefit to COPD patients,
and could improve the Chinese medical signs and symp-
toms in patients with AECOPD, reducing airway inflam-
mation and airway mucus hypersecretion [17,18]. Others
improve lung function and relieve airway inflammation
in patients with stable COPD [19].
Currently, there are no TCM treatments involving
syndrome differentiation therapy for COPD patients;
therefore, we designed this study. The study will be a
large-sample, multicenter, long-term chronic obstructive
pulmonary disease study. The data gathered will shed new
light on traditional Chinese medicine, especially for COPD
treatment.
Trial status
At the time of manuscript submission, we had recruited
150 patients but not completed the patient recruitment.
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